hotspot -WSS

hotspot

author：fashion 2025-09-14 21:58:23 - browse：67

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Wegovy, Zepbound and weight loss drugs that preserve muscle

hotspot

entertainment

WSS

The surgeon had a dilemma only a Nazi medical text could resolve

Humana cuts profit projections as Medicare Advantage costs soar

Prior authorization will have to move faster under new Biden rule

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

eGenesis tests gene

New brain studies show LSD's effects on the brain in full color

hotspot

hotspot

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Independent physicians launch a new lobbying group

Medical records are filled with copy

Eli Lilly, Pfizer, and others want in on the online prescription market

Activists slam private health insurers over coverage restrictions

NYU radiologists take on the challenge of expensive MRI machines

Medicare proposal to cover medical devices draws a mixed reaction

Weight loss drug costs may need more research, senator suggests

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Wikipedia

EU regulator recommends expanding Mounjaro approval to obesity

Surge of respiratory disease in China has likely explanation

Prior authorization will have to move faster under new Biden rule

Copay coupons to count toward deductibles, after Biden court move

eGenesis tests gene

Why doctors need education on FDA device approval process

hotspot

hotspot

entertainment

leisure time